14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
COYA vs GENK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Coya Therapeutics, Inc. (COYA) captures the overall head-to-head institutional edge over GEN Restaurant Group, Inc. (GENK) on higher Unified Composite conviction (64.4/100 BUY vs. 47.6/100 HOLD) after splitting the core matrix 6–2 (led by Options & Positioning), while GENK wins 5–1 across the 6-pillar growth and valuation breakdown. COYA trades at $2.95 (N/M Forward P/E, -636.8% operating margin) versus GENK at $0.81 (N/M Forward P/E, -11.3% operating margin).
Growth vs. Quality Trade-Off: COYA earns the overall head-to-head edge with a stronger Unified Composite Score (64.4/100 BUY vs. GENK 47.6/100 HOLD) and 1.96β · 81% Vol risk profile, whereas GENK leads top-line expansion (-3.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: COYA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9); meanwhile GENK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COYA vs GENK. Trailing 12-month operating profitability (COYA -636.8% vs GENK -11.3%) and valuation multiples (COYA N/M vs GENK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Restaurants value chain with $34.4M market capitalization and -11.3% operating margin.
OpEx & R&D Reinvestment20.0% of Rev ($42M)
90D Engineering Disclosures0 Published
Investor FAQ COYA vs GENK Key Questions & Quantitative Answers
As of Nov 20, 2026, Coya Therapeutics, Inc. (COYA) captures the overall head-to-head institutional edge over GEN Restaurant Group, Inc. (GENK) on higher Unified Composite conviction (64.4/100 BUY vs. 47.6/100 HOLD) after splitting the core matrix 6–2 (led by Options & Positioning), while GENK wins 5–1 across the 6-pillar growth and valuation breakdown. COYA trades at $2.95 (N/M Forward P/E, -636.8% operating margin) versus GENK at $0.81 (N/M Forward P/E, -11.3% operating margin). Growth vs. Quality Trade-Off: COYA earns the overall head-to-head edge with a stronger Unified Composite Score (64.4/100 BUY vs. GENK 47.6/100 HOLD) and 1.96β · 81% Vol risk profile, whereas GENK leads top-line expansion (-3.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: COYA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9); meanwhile GENK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GENK leads the Growth & Scale pillar: COYA posts -93.4% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (N/A gross margin, -636.8% operating margin), compared with GENK at -3.3% YoY revenue growth and -93.6% YoY earnings growth on $208M TTM revenue (8.7% gross margin, -11.3% operating margin). On trailing 12-month operating scale, COYA generates $4.7M in USD-normalized revenue versus $208M for GENK. In operating R&D and SG&A reinvestment, COYA deploys N/A (0 90-day corporate R&D disclosures) versus 20.0% of Rev ($42M) (0 disclosures) for GENK.
GENK screens cheaper on headline valuation multiples. COYA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported FCF margin), whereas GENK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-6.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COYA (-99.2% ROE) versus GENK (-117.1% ROE) capital efficiency.
In options market volatility and institutional positioning, COYA carries 393.8% implied volatility (46th %ile, Balanced (25th–60th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.96β · 81% Vol realized risk). By comparison, GENK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 132% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.